Cell therapy to help prevent AML relapse after transplant
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must agree to the study and return for follow-up visits and treatments as scheduled
- You have been diagnosed with AML (acute myeloid leukemia)
- You received a donor stem cell transplant within about 2 to 3 months (60–100 days), and tests show the donor cells took over fully
- You must be considered high-risk for relapse after transplant, based on specific prior treatment results or test findings
- You should be well enough for study treatment: recent side effects are mild (grade <2), and heart, liver, kidney, and blood counts meet set limits
- You should not have certain conditions, like active leukemia relapse after transplant, serious lung/heart disease, major uncontrolled infections, or certain recent other cancers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This study tests DC-AML immune cells to help people with acute myeloid leukemia (AML) who are in remission but still show signs of leftover cancer cells or relapse risk. It may help the immune system attack AML cells, especially when a stem cell transplant is not an option.
This study tests an “immune cell therapy” made from a family donor to help children and young adults with AML stay in remission after chemotherapy. It may help reduce the chance that AML comes back, but eligibility depends on remission status, donor suitability, and avoiding certain infections or liver issues.
This trial tests a new treatment called NCR300 to try to keep acute myeloid leukemia from coming back after a stem cell transplant. It may help people who have a high risk of relapse or who still have some leukemia cells left after transplant.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.